{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:36:27Z","timestamp":1772138187938,"version":"3.50.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","funder":[{"name":"Instituto Mexicano del Seguro Social (IMSS), Government of Mexico"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Beginning in March 2021, Mexico vaccinated childcare workers with a single-dose CanSino Biologics (Adv5-nCoV) coronavirus disease 2019 (COVID-19) vaccine. Although CanSino is currently approved for use in 10 Latin American, Asian, and European countries, little information is available about its vaccine effectiveness (VE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluated CanSino VE within a childcare worker cohort that included 1408 childcare facilities. Participants were followed during March\u2013December 2021 and tested through severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse-transcription polymerase chain reaction or rapid antigen test if they developed any symptom compatible with COVID-19. Vaccination status was obtained through worker registries. VE was calculated as 100%\u2009\u00d7\u2009(1 \u2212 hazard ratio for SARS-CoV-2 infection in fully vaccinated vs unvaccinated participants), using an Andersen-Gill model adjusted for age, sex, state, and local viral circulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort included 43\u2009925 persons who were mostly (96%) female with a median age of 32 years; 37\u2009646 (86%) were vaccinated with CanSino. During March\u2013December 2021, 2250 (5%) participants had laboratory-confirmed COVID-19, of whom 25 were hospitalized and 6 died. Adjusted VE was 20% (95% confidence interval [CI], 10%\u201329%) against illness, 76% (95% CI, 42%\u201390%) against hospitalization, and 94% (95% CI, 66%\u201399%) against death. VE against illness declined from 48% (95% CI, 33%\u201361%) after 14\u201360 days following full vaccination to 20% (95% CI, 9%\u201331%) after 61\u2013120 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CanSino vaccine was effective at preventing COVID-19 illness and highly effective at preventing hospitalization and death. It will be useful to further evaluate duration of protection and assess the value of booster doses to prevent COVID-19 and severe outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciac488","type":"journal-article","created":{"date-parts":[[2022,6,19]],"date-time":"2022-06-19T14:11:15Z","timestamp":1655647875000},"page":"S167-S173","source":"Crossref","is-referenced-by-count":10,"title":["Vaccine Effectiveness of CanSino (Adv5-nCoV) Coronavirus Disease 2019 (COVID-19) Vaccine Among Childcare Workers\u2014Mexico, March\u2013December 2021"],"prefix":"10.1093","volume":"75","author":[{"given":"Vesta L","family":"Richardson","sequence":"first","affiliation":[{"name":"Direcci\u00f3n de Prestaciones Econ\u00f3micas y Sociales, Instituto Mexicano del Seguro Social , Mexico City , Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mart\u00edn Alejandro","family":"Camacho Franco","sequence":"additional","affiliation":[{"name":"Direcci\u00f3n de Prestaciones Econ\u00f3micas y Sociales, Instituto Mexicano del Seguro Social , Mexico City , Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurora","family":"Bautista M\u00e1rquez","sequence":"additional","affiliation":[{"name":"Direcci\u00f3n de Prestaciones Econ\u00f3micas y Sociales, Instituto Mexicano del Seguro Social , Mexico City , Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Libny","family":"Mart\u00ednez Valdez","sequence":"additional","affiliation":[{"name":"Direcci\u00f3n de Prestaciones Econ\u00f3micas y Sociales, Instituto Mexicano del Seguro Social , Mexico City , Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Enrique","family":"Castro Ceronio","sequence":"additional","affiliation":[{"name":"Direcci\u00f3n de Prestaciones Econ\u00f3micas y Sociales, Instituto Mexicano del Seguro Social , Mexico City , Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Cruz Cruz","sequence":"additional","affiliation":[{"name":"Direcci\u00f3n de Prestaciones Econ\u00f3micas y Sociales, Instituto Mexicano del Seguro Social , Mexico City , Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radhika","family":"Gharpure","sequence":"additional","affiliation":[{"name":"Influenza Division, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn E","family":"Lafond","sequence":"additional","affiliation":[{"name":"Influenza Division, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tat S","family":"Yau","sequence":"additional","affiliation":[{"name":"Influenza Division, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Azziz-Baumgartner","sequence":"additional","affiliation":[{"name":"Influenza Division, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauricio","family":"Hern\u00e1ndez \u00c1vila","sequence":"additional","affiliation":[{"name":"Direcci\u00f3n de Prestaciones Econ\u00f3micas y Sociales, Instituto Mexicano del Seguro Social , Mexico City , Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,6,19]]},"reference":[{"key":"2022101111155336500_ciac488-B1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0140-6736(21)02753-7","article-title":"Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial","volume":"399","author":"Halperin","year":"2022","journal-title":"Lancet"},{"key":"2022101111155336500_ciac488-B2","author":"World Health Organization"},{"key":"2022101111155336500_ciac488-B3","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"2022101111155336500_ciac488-B4","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3390\/vaccines9091047","article-title":"Neutralizing antibodies against SARS-CoV-2, anti-Ad5 antibodies, and reactogenicity in response to Ad5-nCoV (CanSino Biologics) vaccine in individuals with and without prior SARS-CoV-2","volume":"9","author":"Hern\u00e1ndez-Bello","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"2022101111155336500_ciac488-B5","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3390\/vaccines9090999","article-title":"IgG antibodies generation and Side effects caused by Ad5-nCoV vaccine (CanSino Biologics) and BNT162b2 vaccine (Pfizer\/BioNTech) among Mexican population","volume":"9","author":"Guzm\u00e1n-Mart\u00ednez","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"2022101111155336500_ciac488-B6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3390\/vaccines9030227","article-title":"SARS-CoV-2 neutralizing antibodies: a network meta-analysis across vaccines","volume":"9","author":"Rogliani","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"2022101111155336500_ciac488-B7","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.vaccine.2022.03.067","article-title":"Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: evidence from an outbreak in Yunnan, China, 2021","volume":"40","author":"Ma","year":"2022","journal-title":"Vaccine"},{"key":"2022101111155336500_ciac488-B8","author":"Ministry of Health Mexico"},{"key":"2022101111155336500_ciac488-B9","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMe2202547","article-title":"Addressing vaccine inequity\u2014Covid-19 vaccines as a global public good","volume":"386","author":"Hunter","year":"2022","journal-title":"N Engl J Med"},{"key":"2022101111155336500_ciac488-B10","author":"Pan American Health Organization"},{"key":"2022101111155336500_ciac488-B11","author":"World Health Organization"},{"key":"2022101111155336500_ciac488-B12","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/jamapediatrics.2021.2770","article-title":"Association of age and pediatric household transmission of SARS-CoV-2 infection","volume":"175","author":"Paul","year":"2021","journal-title":"JAMA Pediatr"},{"key":"2022101111155336500_ciac488-B13","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2107058","article-title":"Prevention and attenuation of Covid-19 with the BNT162b2 and mRNA-1273 vaccines","volume":"385","author":"Thompson","year":"2021","journal-title":"N Engl J Med"},{"key":"2022101111155336500_ciac488-B14","author":"Pan American Health Organization"},{"key":"2022101111155336500_ciac488-B15","author":"Ministry of Health of M\u00e9xico"},{"key":"2022101111155336500_ciac488-B16","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3390\/v14010154","article-title":"Prevalence of SARS-CoV-2 variants of concern and variants of interest in COVID-19 breakthrough infections in a hospital in Monterrey, Mexico","volume":"14","author":"Gal\u00e1n-Huerta","year":"2022","journal-title":"Viruses"},{"key":"2022101111155336500_ciac488-B17","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.15585\/mmwr.mm7034e4","article-title":"Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection among frontline workers before and during B.1.617.2 (Delta) variant predominance\u2014eight U.S. locations, December 2020\u2013August 2021","volume":"70","author":"Fowlkes","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022101111155336500_ciac488-B18","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression","volume":"399","author":"Feikin","year":"2022","journal-title":"Lancet"},{"key":"2022101111155336500_ciac488-B19","author":"Ministry of Health of Chile"},{"key":"2022101111155336500_ciac488-B20","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1056\/NEJMoa2110362","article-title":"Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings","volume":"385","author":"Thompson","year":"2021","journal-title":"N Engl J Med"},{"key":"2022101111155336500_ciac488-B21","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.cmi.2021.10.005","article-title":"Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review","volume":"28","author":"Fiolet","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2022101111155336500_ciac488-B22","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","article-title":"Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study","volume":"398","author":"Tartof","year":"2021","journal-title":"Lancet"},{"key":"2022101111155336500_ciac488-B23","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1002\/jmv.27688","article-title":"Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: a systematic review","volume":"94","author":"Notarte","year":"2022","journal-title":"J Med Virol"},{"key":"2022101111155336500_ciac488-B24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.15585\/mmwr.mm7107e2","volume":"71","author":"Ferdinands","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022101111155336500_ciac488-B25","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.15585\/mmwr.mm7044e2","article-title":"The Advisory Committee on Immunization Practices\u2019 interim recommendations for additional primary and booster doses of COVID-19 vaccines\u2014United States, 2021","volume":"70","author":"Mbaeyi","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022101111155336500_ciac488-B26","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.15585\/mmwr.mm7038e1","article-title":"Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions\u2014United States, March\u2013August 2021","volume":"70","author":"Self","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022101111155336500_ciac488-B27","doi-asserted-by":"crossref","first-page":"656","DOI":"10.3390\/vaccines10050656","article-title":"Clinical and immunologic efficacy of the recombinant adenovirus type-5-vectored (CanSino Bio) Vaccine in University professors during the COVID-19 Delta wave","volume":"10","author":"Guzm\u00e1n-L\u00f3pez","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"2022101111155336500_ciac488-B28","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMoa2116414","article-title":"Homologous and heterologous Covid-19 booster vaccinations","volume":"386","author":"Atmar","year":"2022","journal-title":"N Engl J Med"},{"key":"2022101111155336500_ciac488-B29","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1473-3099(22)00178-5","article-title":"Emerging evidence on heterologous COVID-19 vaccine schedules\u2014to mix or not to mix?","volume":"22","author":"Parker","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2022101111155336500_ciac488-B30","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/irv.12975","article-title":"Anti-SARS-CoV-2 IgG antibody levels among Thai healthcare providers receiving homologous and heterologous COVID-19 vaccination regimens","volume":"16","author":"Kittikraisak","year":"2022","journal-title":"Influenza Other Respir Viruses"},{"key":"2022101111155336500_ciac488-B31","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3390\/vaccines10030400","article-title":"Efficacy and safety of heterologous booster vaccination after Ad5-nCoV (CanSino Biologics) vaccine: a preliminary descriptive study","volume":"10","author":"Mu\u00f1oz-Valle","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"2022101111155336500_ciac488-B32","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.vaccine.2019.11.025","article-title":"Does having a seasonal influenza program facilitate pandemic preparedness? An analysis of vaccine deployment during the 2009 pandemic","volume":"38","author":"Porter","year":"2020","journal-title":"Vaccine"},{"key":"2022101111155336500_ciac488-B33","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1016\/j.vaccine.2021.05.099","article-title":"Evaluation of post-introduction COVID-19 vaccine effectiveness: summary of interim guidance of the World Health Organization","volume":"39","author":"Patel","year":"2021","journal-title":"Vaccine"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciac488\/44136903\/ciac488.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/Supplement_2\/S167\/46433985\/ciac488.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/Supplement_2\/S167\/46433985\/ciac488.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T07:17:48Z","timestamp":1665472668000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/75\/Supplement_2\/S167\/6611492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,19]]},"references-count":33,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2022,6,19]]},"published-print":{"date-parts":[[2022,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac488","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.04.14.22273413","asserted-by":"object"}]},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10,1]]},"published":{"date-parts":[[2022,6,19]]}}}